AIM: To assess changes in circulating incretin levels and body fat compositions with initial combination therapy with a-glucosidase inhibitor and dipeptidyl peptidase-4 inhibitor in @entity1 with @entity2175 ( @entity2175 ). METHODS: In this multicenter open-label 24-week trial, Japanese over-weight (BMI>= 25kg/m(2)) @entity1 with @entity2175 not taking medication or taking @entity2449 and/or @entity4136 were randomly assigned to receive either 50mg of @entity35855 three times a day (M, n=14), 50mg of @entity12350 once a day (S, n=14), or a combination of both (M+S, n=13). Changes in plasma incretin levels during a meal tolerance test ( @entity98 ) and body fat composition with impedance method were evaluated. RESULTS: During @entity98 , postprandial plasma @entity413 levels decreased more after M+S than after M or S, and postprandial serum insulin levels decreased significantly after M and M+S whereas they increased after S. After M, active gastric inhibitory polypeptide (aGIP) decreased significantly at 30min despite a significant increase at 120min. After S, aGIP levels increased significantly throughout the @entity98 . After M+S, aGIP increased significantly at 0 and 120min despite of significant decrease at 30min. M+S further enhanced postprandial active @entity5445 levels during @entity98 than S did. Total body fat mass decreased significantly after M and M+S. Visceral fat mass decreased significantly only after M+S. Serum @entity1254 increased significantly only after M+S. CONCLUSIONS: In over-weight @entity1 with @entity2175 , M+S may have a beneficial effect on adiposity with relation to these different effects on two incretins.

Effects of @entity35855 , XXXX , and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese @entity1 with @entity2175 . "The MASTER randomized, controlled trial".

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D'] @entity35855 :: ('MESH:C045621', 'Chemical') :: ['miglitol'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity1254 :: ('9370', 'Gene') :: ['adiponectin'] @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin'] @entity4136 :: ('CHEBI:26831', 'Chemical') :: ['sulfonylurea'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide-1'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity12350 :: (MESH:C496398,Chemical) :: ['sitagliptin']
